Studio City, CA, United States of America

Marc Besman

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 193(Granted Patents)

Location History:

Studio City, CA (US) (2003 - 2017)
Seattle, WA (US) (2012 - 2021)

Company Filing History:

8 out of 759

University of Connecticut

Baxter International Inc.

patents

4. 2 out of 103

Cell Therapeutics, Inc.

patents

5. 1 out of 1,993

The State University of New York

patents

6. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2021

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11020459 - Factor VIII formulations (2021-06-01),

2. 10512674 - Factor VIII formulations (2019-12-24),

3. 9669076 - Albumin-free factor VIII formulations (2017-06-06),

4. 9352027 - Albumin-free factor VIII formulations (2016-05-31),

5. 8765665 - Albumin-free factor VIII formulations (2014-07-01),

6. 8748577 - Conjugates of biologically active polypeptides having an increased in vivo half-life (2014-06-10),

7. 8372800 - Albumin-free factor VIII formulations (2013-02-12),

8. 8129348 - Conjugates of biologically active proteins having a modified in vivo half-life (2012-03-06),

9. 8058226 - Albumin-free factor VIII formulations (2011-11-15),

10. 7625584 - Method of complexing a protein by the use of a dispersed system and proteins thereof (2009-12-01),

11. 7247707 - Albumin-free factor VIII formulations (2007-07-24),

12. 7087723 - Albumin-free factor VIII formulations (2006-08-08),

13. 6586573 - Albumin-free Factor VIII formulations (2003-07-01),

Title: The Innovative Journey of Marc Besman

Introduction

Marc Besman is a notable inventor located in Studio City, California. With a robust portfolio of 13 patents, Besman has made significant contributions to the field of biotechnology, specifically in the formulation of Factor VIII, which is vital in treating hemophilia. His work exemplifies innovation and dedication to advancing medical technologies.

Latest Patents

Marc Besman's most recent patents focus on the formulations of Factor VIII. These compositions are notably designed to eliminate sodium chloride (NaCl) from the final formulation or allow it in only trace amounts. This innovative approach not only reduces the lyophilization cycle time but also enhances the stability of the lyophilized Factor VIII. This development marks a significant improvement in hemophilia treatments, making therapies more efficient and effective for patients.

Career Highlights

Throughout his career, Marc has worked with esteemed organizations such as the University of Connecticut and Baxalta GmbH. His affiliation with these institutions has provided him with a platform to explore and develop groundbreaking inventions in the field of biotechnology.

Collaborations

Marc Besman has collaborated with prominent figures in the industry, including Erik Bjornson and Feroz Jameel. These collaborations have fostered an environment of shared knowledge and innovation, enabling breakthroughs in Factor VIII formulations.

Conclusion

Marc Besman’s contributions to the field of biotechnology underscore the impact of innovative thinking in medicine. Through his patents and collaborations, he continues to pave the way for advancements that improve patient outcomes in hemophilia treatment. His journey exemplifies the power of persistence and creativity in scientific invention.

This text is generated by artificial intelligence and may not be accurate.